Mega%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520cv

# Mega-cv ## Overview Mega-cv is a combination medication containing amlodipine, a dihydropyridine calcium channel blocker, and benazepril, an angiotensin-converting enzyme (ACE) inhibitor. It is used to treat hypertension. ## Primary Indications Hypertension. ## Adult Dosing The typical starting dose is one tablet once daily. Doses are individualized based on patient response and tolerance. * **Starting dose:** 5/10 mg (amlodipine/benazepril) once daily. * **Maximum dose:** 10/40 mg once daily. Dose adjustments should be made cautiously. ## Pediatric Dosing The safety and efficacy of Mega-cv in pediatric patients have not been established. ## Dose Adjustments * **Renal impairment:** For patients with severe renal impairment (creatinine clearance <30 mL/min), starting doses should be lower, and titration should be done carefully. Specific dose recommendations vary, and consultation with renal dosing guidelines is advised. * **Hepatic impairment:** Caution is advised in patients with hepatic impairment. Amlodipine may be poorly tolerated in these patients. Start with lower doses and titrate slowly. ## Contraindications * Hypersensitivity to amlodipine, benazepril, other dihydropyridines, or ACE inhibitors. * History of angioedema related to previous ACE inhibitor treatment. * Hereditary or idiopathic angioedema. * Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment. * Second or third trimester of pregnancy. ## Adverse Effects Common adverse effects include peripheral edema, dizziness, headache, flushing, fatigue, cough, and hyperkalemia. Less common but serious adverse effects include angioedema, hypotension, renal impairment, and hepatic dysfunction. ## Key Drug Interactions * **Diuretics/Other Antihypertensives:** Additive hypotensive effects. * **Potassium Supplements/Potassium-Sparing Diuretics:** Increased risk of hyperkalemia. * **NSAIDs:** May diminish the antihypertensive effect of benazepril and increase the risk of renal dysfunction. * **Lithium:** ACE inhibitors can increase serum lithium levels, leading to lithium toxicity. * **mTOR Inhibitors (e.g., sirolimus, everolimus):** Increased risk of angioedema. ## Monitoring * **Blood pressure:** Regular monitoring to assess efficacy and prevent hypotension. * **Renal function:** Serum creatinine and BUN, especially in patients with pre-existing renal disease or those taking diuretics. * **Serum potassium:** Monitor for hyperkalemia, particularly in patients with renal impairment or those taking potassium supplements. * **Signs of angioedema:** Educate patients on the signs and symptoms. ## Clinical Pearls * Due to the amlodipine component, peripheral edema is a common dose-limiting side effect. * The cough associated with benazepril is typically non-productive and may occur in up to 20% of patients. * Consider potential for drug-induced angioedema, especially in patients with a history of allergies or asthma. * Initiate therapy at the lowest effective dose and titrate based on clinical response. --- **Disclaimer:** This information is intended for healthcare professionals. Always consult the current prescribing information and relevant literature for complete and up-to-date guidance before prescribing.